221 related articles for article (PubMed ID: 24312329)
21. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients.
Hauschild A; Michaelsen J; Brenner W; Rudolph P; Gläser R; Henze E; Christophers E
Melanoma Res; 1999 Apr; 9(2):155-61. PubMed ID: 10380938
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
23. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
24. Increased CCL17 serum levels are associated with improved survival in advanced melanoma.
Weide B; Allgaier N; Hector A; Forschner A; Leiter U; Eigentler TK; Garbe C; Hartl D
Cancer Immunol Immunother; 2015 Sep; 64(9):1075-82. PubMed ID: 25990074
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
[TBL] [Abstract][Full Text] [Related]
26. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients.
Lagerwaard FJ; Levendag PC; Nowak PJ; Eijkenboom WM; Hanssens PE; Schmitz PI
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(4):795-803. PubMed ID: 10098435
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694.
Tarhini AA; Stuckert J; Lee S; Sander C; Kirkwood JM
J Clin Oncol; 2009 Jan; 27(1):38-44. PubMed ID: 19047287
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for survival of patients treated systemically for disseminated melanoma.
Eton O; Legha SS; Moon TE; Buzaid AC; Papadopoulos NE; Plager C; Burgess AM; Bedikian AY; Ring S; Dong Q; Glassman AB; Balch CM; Benjamin RS
J Clin Oncol; 1998 Mar; 16(3):1103-11. PubMed ID: 9508197
[TBL] [Abstract][Full Text] [Related]
29. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
30. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis.
Mocellin S; Zavagno G; Nitti D
Int J Cancer; 2008 Nov; 123(10):2370-6. PubMed ID: 18752249
[TBL] [Abstract][Full Text] [Related]
32. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
[TBL] [Abstract][Full Text] [Related]
33. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
34. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
Gao D; Ma X
Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
[TBL] [Abstract][Full Text] [Related]
35. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.
Mohammed MQ; Abraha HD; Sherwood RA; MacRae K; Retsas S
Med Oncol; 2001; 18(2):109-20. PubMed ID: 11778756
[TBL] [Abstract][Full Text] [Related]
36. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
[TBL] [Abstract][Full Text] [Related]
37. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
39. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma.
Cao MG; Auge JM; Molina R; Martí R; Carrera C; Castel T; Vilella R; Conill C; Sánchez M; Malvehy J; Puig S
Anticancer Res; 2007; 27(1B):595-9. PubMed ID: 17348447
[TBL] [Abstract][Full Text] [Related]
40. High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
Weide B; Schäfer T; Martens A; Kuzkina A; Uder L; Noor S; Garbe C; Harter PN; Mittelbronn M; Wischhusen J
J Invest Dermatol; 2016 Dec; 136(12):2444-2452. PubMed ID: 27705749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]